|| µn¤J¡U ½s¿è¡UÆ[¬Ý¡U ¬ã²ß³ø§i¡U ³ø§i®æ¦¡¤U¸ü¡U ¤W¶Ç³ø§i¡U¬d¸ß¡U µn¥X¡U| ¡·µn¤J«á§Y¥i½s¿è¤ß±o¤Î¤W¶Ç³ø§i¡I

[¦^¾ð¼w­º­¶]

¥D¦®¡G °ª¶¯¥«98¾Ç¦~«×´¶³q°ª¯Å¤¤¾Ç½Òµ{¹Ù¦ñ¾Ç²ß¸s±Ð®v±M·~¦¨ªø¬ã²ß
¨Ì¾Ú¡G ±Ð¨|³¡98¾Ç¦~«×´¶³q°ª¯Å¤¤¾Ç½Òµ{¹Ù¦ñ¾Ç²ß¸s±Ð®v±M·~¦¨ªø¬ã²ß­pµeº[°ª¶¯¥«±Ð¨|§½98.09.30°ª¥«±Ð¤@¦r098041392¸¹
¬ã²ß¦aÂI¡G «eÂí°ª¤¤
¬ã²ß®É¶¡¡G098/12/02   
µoªíªÌ¡G³¯¾ì«F ¤å³¹Ãþ§O¡G¬ã²ß¤ß±o µoªí¤é´Á¡G098/12/02
³Q¶}Ū¦¸¼Æ¡G8217 ¦¸
¤ß±o¤º®e¡G ¤å¦r©ñ¤j ¤å¦rÁY¤p¡@ ¦^¤W­¶
   

¤@.¤HÅ骺§K¬Ì¨t²Î
¤HÅ骺§K¬Ì¨t²Î¥i¥H¤À¦¨innate immunity ©Macquired immunity¨â­Ó³¡¤À¡A·í¥~¨Ó¯f­ì¤J«I¤HÅé®É¡A­º¥ý¬O¥Ñ¥i¥H¿ëÃÑpathogen-associated molecular patterns (PAMPs)ªºinnate immunity¶}©l¶i¦æ¨¾¿mªº¤u§@¡A¦Ó·íinnate immunity¨S¦³¿ìªk§¹¥þªº²M°£¯f­ì®É¡A¤~¥Ñ¨ã¦³¿ëÃѱM¤@©Ê°ªªºacquired immunity¨Ó²M°£¥~¨Ó¤J«Iª«¡C
¤G.«D±M¤@©Ê§K¬Ì§@¥Î
¨Ò¦p¡G
(1) ¥Ö½¤«Ì»Ù
(2) µoª¢¤ÏÀ³¡G¬õ¡B¸~¡B¼ö¡Bµh¯gª¬
(3) §]¾½§@¥Î¡G§]¾½²Ó­M
¤T.¤°»ò¥s°µ Toll-like receptors
§K¬Ì²Ó­M¤W¦³¤@¸s¨üÅé¡A¥Î¨Ó°»´ú¦UºØ¥~¨Óª«½è¡AºÙ°µ¡uÃþÅM¨üÅé¡v¡]toll-like receptor, TLR¡^¡A¥D­n°Ñ»P¥¼¤Þµo±M¤@©Ê§ÜÅ骺¡u«D¯S²§©Ê§K¬Ì¤ÏÀ³¡v¡C¤£¦PªºÃþÅM¨üÅé¦U¦³­t³d°»´úªº¹ï¶H¡A¨Ò¦pTLR3­t³d°»´ú¥~¨ÓªºÂùªÑRNA¯f¬r¡A¦Ó TLR4­t³d·j´M²Óµßªº¤º¬r¯À¯×¦hÁÞ¡A¦ÓTrif§Y¬O³oÃþ¨üÅé©Ò¦@¥Îªº¶Ç°T¤À¤l¡C
¥|. Toll-¼Ë¨üÅé
•Toll-¼Ë¨üÅé¡A¬°¤@¸û«O¦u¤£Åܪº¨üÅé³J¥Õ®a±Ú¡C¬O¼Ò¦¡ÃѧO¨üÅé(pattern recognition receptor , PRR)¡A¼sªx¤À¥¬©ó§K¬Ì²Ó­M¡A¥iÃѧO¦hºØ¯f­ì·L¥Íª«¬ÛÃöªº¤À¤l¼Ò¦¡¡A¦p¦h¿}¡B¬O¥Íª«-·L¥Íª«¦@¦Pºt¤Æªº¦Ñ¬ÛÃÑ¡A©Ò¥H¤H±`¹ï·sªº¯f­ìÅé¸û§ô¤âµLµ¦¡A¦Ñ¬ÛÃѪº¥j¦Ñ¯f­ì¡A±`¤â¨ì¾à¨Ó¡A¤T¨â¤U´N·d©w¡C
•TLR¦b¥Í¤Ñ§K¬Ì¤Î«á¤Ñ§K¬Ì¨t²Î¬Ò°_­«­n§@¥Î¡C
TLRªº¨üÅ骺°tÅé(ligand)§Y§Ü¡A­ì¥i¤À¥~·½©Ê¤Î¤º·½©Ê
¡E¥~·½©Ê¡Ð¨Ó¦Û¯f­ì·L¥Íª«
¡E¤º·½©Ê¡Ð¨Ó¦ÛÅ餺À³¿E©Î²Õ´¨ü·l©ÒÄÀ¥Xªº¤À¤l
¤­. TLR¦b§K¬Ì½Õ±±¦³¦ó§@¥Î?
•1.TLR¼sªx¦s¦b©ó¥ý¤Ñ§K¬Ì²Ó­M¡C
•2.¯f­ì¤J«I¡ATLR³Q¯f­ì¬ÛÃö¤À¤l¼Ò¦¡¿E¬¡¡A°£¤Àªc¤j¶q²Ó­M¦]¤l¡A¤]¥iª½±µ¥[±j¥ý¤Ñ§K¬Ì¨t²Îªº±þµß¯à¤O¡A¾É¤W¥Ö²Ó­M²£¥Í²Ó­M¦]¤l¡AÁͤƦ]¤l¤Î§Ü·L¥Íª«¦h肽¡C
•3.TLR¯à½Õ±±«á¤Ñ§K¬Ì²Ó­M¡A³z¹L¾ðª¬²Ó­M¤Î¤Àªcªº²Ó­M¦]¤l¡A¹ïT²Ó­M©MB²Ó­M¦³¿E¬¡§@¥Î¡A¤]»¤¾É²£¥ÍÉC«¬¤zÂZ¯À¡C
4.TLR¯à½Õ±±§K¬Ì²Ó­M¦Ü·P¬V³¡¦ì¡C
5.TLR½Õ±±Th1/Th2§K¬Ì¥­¿Å¡ATLR©MPlR¨M©w¤£¦¨¼ôªº¾ðª¬²Ó­M(DCi)¦¨¼ô¦¨½Õ¸`DC¡A²Ä¤@«¬DC©M²Ä¤G«¬DC¡A¨Ì¨Ï¦ÛµMT²Ó­M¤À¤Æ¦¨½Õ¸`T²Ó­M(Tre)¡A¤@«¬T²Ó­M©M²Ä¤G«¬T²Ó­MTreg¤ÀªcTGF-B©MIL-10§í¨îTh1©MTh2¡C
¤». ¤°»ò¥s°µ Toll-like receptors
1. Toll receptors¬O1988¦~¥ª¥k¦bªGÃÇÅ餺¥ýµo²{ªº¡A³o¨Çreceptors¦b±µ¦¬¨ì¥~¨Ó¯f­ìªº¨ë¿E«á¡A¥i¥H¤Þµo¤@³s¦êªºsignalling pathway¡A¨Ï±oimmune system¶}©l¦³©Ò¤ÏÀ³¡CÀH«á¡A¦b­÷¨ÅÃþ°Êª«¤]µo²{©MToll¬Û¦ü«×·¥°ªªºreceptors¡AºÙ¬°Toll-like receptors (TLRs)¡C¥Ø«e©Òª¾ªºToll-like receptors ¦@¦³10ºØ¡A¤À§O±qTLR1¨ìTLR10¡A¥¦­Ì¤À§O¿ëÃѤ£¦PªºPAMPs ¡C
2. ·íTLR¿ëÃѨì³o¨ÇPAMPs«á¡AÂÇ¥Ñreceptorsªºintracellular signalling domain, the Toll/interleukin-1 receptor (TIR) domain¥H¤Î¤U´åªºadaptor protein MyD88¡A±N°T®§¶Ç»¼¤U¥h¡A¨Ã¤Þµo²Ó­M¤@¨Ç°ò¦]ªºªí²{¡C
¤C. Cell Types of Innate Immunity
¶Ý¤¤©Ê¥Õ¦å²y¦b³o¥ý¤Ñ©Ê§K¬Ì¤ÏÀ³´N¬O§êºt«D±`­«­n¤]¬O¥D­nªº¨¤¦â¡A¦]¬°¶Ý¤¤©Ê¥Õ¦å²y³q±`¬O³Ì¥ý³Q¬¡¤Æ¦Ó¥B³Ì§Ö¨ì¹F¤@¨Ç¥¿¦bµoª¢ªº§½³¡°Ï°ì¡A¯S§O¬O²Óµß©Êªº·P¬V©Ò³y¦¨¦­´Á§K¬Ì¤ÏÀ³¡C
¶Ý¤¤©Ê¥Õ²Ó­M¬O©è§Ü·L¥Íª««I¤Jªº²Ä¤@¹D¨¾½u¡A¨ã¦³ÅܧλP§]¾½¯à¤O¡A¦b©è§Ü¯e¯f¡B«OÅ@¾÷Åé¤è­±«D±`­«­n¡C¶Ý¤¤©Ê¥Õ¦å²y¤§©Ò¥H¯à°÷¨­­t­«¥ô¨Ã§¹¦¨¨Ï©R¦³¨â¶µ­«­nªº¥²³Æ±ø¥ó¡G
1.¶Ý¤¤©Ê¥Õ¦å²y­n¯à°÷§Ö³t¦Ó¥B¥¿½T¤è¦Vªº²¾°Ê¨ì¥¿¦bµoª¢ªº­P¯f­ì°Ï°ì¡C
2.¶Ý¤¤©Ê¥Õ¦å²y¦b¹ï§Ü­P¯fµß¦³«Ü¦h¤wª¾¤è¦¡¡A°£¤Fª½±µ¹ï­P¯f·½¶i¦æ§]¾½§@¥Î¡A¥t¥~ÁÙ¥]¬A¤Àªc¤@¨Ç¤À¸Ñ»Ã¯À¦pperoxidase (MPO)¡ALysozyme©MElastase¡A©ÎªÌ¬O¤Àªc¤@¨Ç¹L®ñ¤Æª«¦pROS¡ANO©MSuperoxide anion ¡C
¤E.«á¤Ñ©Ê§K¬Ì©Î¾AÀ³©Ê§K¬Ì
·í¤J«IªÌ¨S¦³³Q¨­Å骺«D±M¤@©Ê¨t²Î¡]¥ý¤Ñ©Ê§K¬Ì¡^ºR·´®É¡A«á¤Ñ©Ê§K¬Ì´N·|±Ò°Ê¡C
ƒá1.²O¤Ú²Ó­M
ƒá2.¥D­n²Õ´¬Û®e½Æ¦XÅé(MHC)
ƒá3.§ÜÅé
¤Q.«á¤Ñ©Ê§K¬Ì
«á¤Ñ©Ê§K¬Ì¬O¸g¥Ñ¦hºØÃþ«¬²Ó­M¤Î¦¨¤À¬Û¤¬¨ó¤O§@¥Î©Òºc¦¨ªº¡C¦³¨âºØ¥D­nÃþ«¬ªº«á¤Ñ©Ê§K¬Ì¡G²Ó­M´C¤¶ªº§K¬Ì©M§ÜÅé´C¤¶ªº§K¬Ì¡C
¤Q¤G. ¥D­n²Õ´¬Û®e½Æ¦XÅémajor histocompatibility complex (MHC)
¡V¤HÃþMHC°ò¦]ºÙ¬°¤HÃþ¥Õ¦å²y§Ü­ìHLA, human leukocyte antigen (¦ì©ó²Ä¤»¹ï¬V¦âÅé)
¡V¤À¬°¨âÃþ
•MHC class I
¡V°£¤F¸¢Åé¡B¤¤¼Ï¯«¸g¡B­L½L²Ó­M¥~¡A¨ä¥L²Ó­M³£¦³
¡V¯f¬r·P¬V²Ó­M§Ü­ì§e²{§@¥Î
•MHC class II
¡V§Ü­ì§e²{²Ó­M¡G¾ð¬ð¡B¥¨¾½²Ó­M¡BB²O¤Ú²y¡B¨ü²Ó­M¿E¯À¨ë¿Eªº¦åºÞ¤º¾À²Ó­M¡Bªí¥Ö²Ó­M
¡V­M¥~ªº§Ü­ì§e²{§@¥Î
¡V¥\¯à¬°¬¡¤ÆT²O¤Ú²y
¤Q¤T.²O¤Ú²Ó­M
1. ¤TºØ¥D­nªº²O¤Ú²Ó­M°Ñ»P§K¬Ì¨t²Î¡CT²Ó­M©MB²Ó­M¦b«á¤Ñ§K¬Ì¨t²Î¤¤§êºt­«­n¨¤¦â¡A¦Ó¦ÛµM±þ¤â²Ó­M«h°Ñ»P¥ý¤Ñ©Ê§K¬Ì¡C
2. ¬ù¦³¢µ¢¯¢Hªº²O¤Ú²Ó­M¬O¢â²Ó­M¡A¦¹²Ó­M¦b°©Å褤µo¨|«á¾E²¾¨ì¯Ý¸¢¡A¦b¯Ý¸¢¦¨¼ô¨ÃÀò±o¯à¤O¥H¹ï§Ü·P¬V¡C
3.®Ú¾ÚB²Ó­Mªº¥\¯à¡A¤À¬°¤TºØÃþ«¬¡G¥®¸X(naive)B²Ó­M
¦å¼ß²Ó­M(plasma cells) ¡A °O¾Ð²Ó­M(memory B cells

¤Q¤­. T ²O¤Ú²Ó­M
²Ó­M¬rT²Ó­M¡]cytotoxic T cell¡^¡G®ø·À¨ü·P¬Vªº²Ó­M¡C³o¨Ç²Ó­Mªº¥\¯à´N¹³¤@­Ó¡u±þ¤â¡v©Î²Ó­M¬r¯À¨º¼Ë¡A¦]¬°¥¦­Ì¥i¥H¹ï²£¥Í¯S®í§Ü­ì¤ÏÀ³ªº¥Ø¼Ð²Ó­M¶i¦æ±þ·À¡C²Ó­M¬rT²Ó­Mªº¥D­nªí­±¼Ð»x¬OCD8,¤]³QºÙ¬°±þ¤âT²Ó­M¡C
»²§UT²Ó­M¡]helper T cell¡^¦b§K¬Ì¤ÏÀ³¤¤§êºt¤¤¶¡¹Lµ{ªº¨¤¦â¡G¥¦¥i¥H¼W¥ÍÂX´²¨Ó¿E¬¡¨ä¥¦Ãþ«¬ªº²£¥Íª½±µ§K¬Ì¤ÏÀ³ªº§K¬Ì²Ó­M¡C»²§UT²Ó­Mªº¥D­nªí­±¼Ð»x¬OCD4¡C T²Ó­M½Õ±±©Î¡u»²§U¡v¨ä¥¦²O¤Ú²Ó­Mµo´§¥\¯à¡C¥¦­Ì¬O¤wª¾ªºHIV¯f¬rªº¥Ø¼Ð²Ó­M¡A¦b·R´þ¯fµo¯f®É·|«æ¼@´î¤Ö¡C
¤Q¤». Treg cells ½Õ±±T²Ó­M
•¦³¤@¸s½Õ±±T²Ó­M(Regulatory T cells, Treg cells)¡A¥D­nªº¥\¯à¬Oºû«ù§K¬Ìªº¦ÛÅé§Ü­ì­@¨ü©Ê(self-tolerance)¡A©Ò¥H·íÅ餺Treg cellsµo¥Í¯Ê³´®É¡A·|¤Þ°_¦ÛÅé§K¬Ì¯e¯f¡C
•¤j³¡¤À¦ÛµM²£¥ÍªºTreg cells·|ªí²{CD4¡BCD25©MFoxp3¡AFoxp3¬O½Õ±±Treg cellsµo¨|¤Î¥\¯àªº­«­nÂà¿ý¦]¤l¡C
•¥Ø«e³\¦h¬ã¨s­P¤O©óÀò±o¤j¶qªºFoxp3+ Treg cells¥Î¦bªvÀø¤W¡A¦ý¨ä¹ê²Ó­M¤º½Õ±±Treg cells¦s¬¡ªº¾÷¨î¤´¥¼Âç²M¡C
¤Q¤C. Treg cells
•½Õ¸`«¬T²Ó­M(Treg cell)¥i¥H§í¨îTh1©MTh2ªº¬¡©Ê¡A¦³ÂIÃþ¦ü¨­Å骺°jõX§í¨î§@¥Î¡ATreg cell¥i¥H³Q¯S²§©Êªº§Ü­ì(¨Ò¦p¤G«¬½¦­ì³J¥Õ)»¤¾É¡A²£¥Í­@¨ü©Ê§@¥Î¡D
•¤HÃþ½Õ±±T²Ó­M¡]T regulatory cell,. Treg¡^ªº¥D­n¥\¯à¬O§í¨î§K¬Ì¤ÏÀ³¡Aªý¤î. ¹L±Ó¤Îµoª¢¡A¥HÁקK¦ÛÅé§K¬Ì¯e¯fµo ¥Í
¤Q¤K.½Õ±±T²Ó­M
½Õ±±T²Ó­MªººØÃþ¡G
•1. CD4+CD25+ natural Treg¡G§Q¥ÎCTLA-4¡BGITR©ÎFasLµ¥²Ó­M±µÄ²ªº¤è¦¡§í¨î¾ðª¬²Ó­M¡Aªý¤î§K¬Ì²Ó­M¬¡¤Æ¡C
•2. CD4+ adaptive Treg¡G¤À¦¨Th3¥H¤ÎTr1¨âºØ¡A¤ÀªcIL-10©ÎTGF-bµ¥cytokine§í¨î¾ðª¬²Ó­M¡Aªý¤î§K¬Ì¤ÏÀ³¡C
•3. ¦bTreg¯Ê³´ªº¦Ñ¹«¥i¥H¬Ý¨ì¦ÛÅé§K¬Ì¯e¯f¡]¦p¡G²Ä¤@«¬¿}§¿¯f¡^¡B®ð³Ý¥H¤Î¹L±Ó¤ÏÀ³¡C
¤Q¤E. ¬°¬Æ»ò§ÜÅ骺ºØÃþ¤Î±M¤@©Ê¦p¦¹¦h©O¡H
•§ÜÅé¤À¬°¤­Ãþ¡]§Y¤­ºØ ¦P«¬ isotypes¡^¡G§ÜÅ骺¦P«¬¬O¦]¬°¥¦¦³«í©w°Ï¦s¦b¡C§ÜÅ骺¤­ºØÃþ«¬¬O¡G IgG, IgD, IgA, IgE, IgM ¡C¨C¤@ºØÃþ«¬»P¤£¦Pªº§K¬Ì¤ÏÀ³¦³Ãö¡C¨Ò¦p¡A IgG ±`±`§l¤Þ¨ã¦³ ²Ó­M¬r©Ê ¡]cytotoxic¡^ ¡]±þ¶Ë©Ê¡^ªº T- ²Ó­M¡A¨ä¯àºR·´¹v²Ó­M¡C¹Ï¤¤Åã¥Üªº§ÜÅé¬O IgG1 «¬§ÜÅé¡C
Ab repertoire might be 1012 - 1016
¤G¤Q. Generation of immunoglobulin diversity in B cells before encounter with antigen
1.°£¤FB²Ó­M¥H¥~ªºÅé²Ó­M¡A¨ä¦³Ãö§K¬Ì²y³J¥Õªº°ò¦]
¬O§e¤ù¬qªº¡AµLªkªí²{¥X°ò¦]²£ª«¡C
2. B²Ó­M¤º¦³§¹¾ãªº Ig °ò¦]¡A³Q¦³¶¶§Ç¦a¤À§G¦b¦U¬V¦âÅé¤W¥B¦b°ª«×Åܲ§°Ï¡A§t¦³ alternative version¡C
¤G¤Q¤@.Åé²Ó­MÂI¬ðÅÜ
•¬°²£¥Í§ÜÅ骺°O¾Ð«¬ B ²Ó­M©Ò¿W¯Sªº²{¶H¡C
•·í§K¬Ì¤ÏÀ³¦A¦¸ªº¹J¨ìthe same epitope, ¦b³Q¬¡¤Æªº¹Lµ{¤¤»Ý­n¦³T-helper cellÄÀ©ñ²Ó­M¿E¯À¡C
•¦bÅܲ§°Ï¤×¨ä¬O°ª«×Åܲ§°Ï, ¨ä°ò¦]¦bCDR1, CDR2, and CDR3, ·|ÀH¾÷µo¥ÍÂI¬ðÅÜ¡C
•¦p¦¹¥i¨Ï²£¥Íªº§ÜÅé§ó¨ã¿Ë©M¤O
•¬ðÅÜ©M­«²Õ¥i¥H¼W¥[¨ä¦h¼Ë©Ê
¤G¤Q¤G.¦ÛÅé§K¬Ì¯e¯f¤À¦¨¨â¤jÃþ
(1) ¾¹©x±M¤@©Ê(organ-specific) :
§K¬Ì¤ÏÀ³ª½±µ§ðÀ»³æ¿Wªº¾¹©x©Î¸¢Å骺¯S©w¥Ø¼Ð§Ü­ì ¡C
(2)¥þ¨­©Ê¦ÛÅé§K¬Ì¯e¯f(systemic autoimmune) ¥þ¨­©Ê¥Ø¼Ð§Ü­ì
¤G¤Q¤T. ¦ÛÅé§K¬Ì¯e¯fªº­ì¦]
•²Ä¤@ºØ­ì¦]¡A¬O²Óµß©Î¯f¬rªº¶Ç¬V©Ò¤Þ°_ªº¥æ¤e§Ü­ì¤ÏÀ³¡]cross-reaction¡^¡C¬Y¨Ç¯f­ìÅéµ²ºc»P±J¥D¦Û¨­§Ü­ì¬Û¦ü¡AºÙ¤§¤À¤l¬Û¦ü¾Ç»¡¡]molecular mimicry¡^¡C
•²Ä¤GºØ­ì¦]¡A¬O±J¥DÅ餺¥¿±`¥BÁôÂéʪº§Ü­ì³QÄÀ©ñ¥X¨Ó¡A³Q§K¬Ì¨t²Îµø¬°¡u¥~¨Óªº¼Ä¤H¡v¡A¶i¦Ó§ðÀ»¤§ (¹jÂ÷§Ü­ìªº³QÄÀ©ñ)¡C
•²Ä¤TºØ­ì¦]¡A«h¬O¨ã¦³½Õ¸`§K¬Ì¨t²Î¥¿±`¹B§@ªº½Õ¸`©ÊT²Ó­M¥X²{¥\¯à²§±`©Ò­P (½Õ±±²Ó­MÀ£§í§K¬Ì¥¢®Ä)¡C
•²Ä¥|ºØ­ì¦]¡A¦ÛÅé§Ü­ìªº§ïÅÜ¡AÀô¹Ò©ÎÃĪ«§@¥Î¤Þµo¦ÛÅé§Ü­ìªº§ïÅÜ¡C
•²Ä¤­ºØ­ì¦]¡A¬OMHC°ò¦]ªº¼vÅT¡A¥ç§Y¿ò¶Ç(¿ò¶Ç¦]¯À)¡C
•²Ä¤»ºØ­ì¦]¡A²O¤Ú²Ó­M¦¨¼ô¹Lµ{¤¤¿z¿ï¿ù»~¡C
¤G¤Q¥|.±`¨£ªº¦ÛÅé§K¬Ì¯e¯f
•¬õ´³ ©Ê¯T½H
•Ãþ­·Àã©ÊÃö¸`ª¢
•µw¥Ö¯f
•¦hµo©Ê¦Ùª¢»P¥Ö¦Ùª¢
•¦åºÞª¢
•­×®æÄõSjogren¯g­Ô¸sµ¥
¤G¤Q¤­.¤°»ò¬OÃþ­·Àã©ÊÃö¸`ª¢
Ãþ­·Àã©ÊÃö¸`ª¢¬O¤@ºØ¦ÛÅé§K¬Ì¤£¥þ©Ò¤Þµoªº¯e¯f¡A·|³y¦¨Ãö¸`ªººC©Êµoª¢¡A¦³®É¤]·|«I¥ÇÃö¸`ªº©P³ò²Õ´©ÎªÌ¬O¨­Åé¨ä¥L¾¹©x¡C¤Þ°_Ãþ­·Àã©ÊÃö¸`ª¢ªº¯u¥¿­ì¦]¤£²M·¡¡C¬O¦ÛÅé§K¬Ì¿ù»~¦a«I¥Ç¦Û¤vÅ餺ªº²Õ´¡A¦Ó²£¥Íµoª¢¤ÏÀ³¡AÃþ­·Àã©ÊÃö¸`ª¢¬O¤@ºØºC©Ê¯f¡A¯gª¬¥i¯à«ùÄò¼Æ¦~¡A¦Ó¥B·|¤ÏÂеo¥Í¡C
¤G¤Q¤».Ãþ­·Àã©ÊÃö¸`ª¢¦³¤°»ò¯gª¬¡H
Ãþ­·Àã©ÊÃö¸`ª¢ªº¯gª¬¥D­n¦³Ãö¸`¬õ¡B¸~¡B¼ö¡Bµh¡CÃö¸`»øµw¡A¦³¹ïºÙ©Ê¡A¤@¯ë³£¥ý«I¥Ç¤â¡BµÃªº¤pÃö¸`¡A©P³ò²Õ´¦p¶´±a¡B¦Ù¸x©M¦Ù¦×¤]·|¦³¬Û¦Pªº¯gª¬¡C±wªÌ·|ı±o¯h­Â¡A­¹¼¤¤£¨Î¡A»´·Lµo¿N¡CÃö¸`¦Ù¦×»øµw¡A¦b²M±á¤×¨ä©úÅã¡A¦³¨Ç¯gª¬ÄY­«ªº±wªÌ¡A¬Æ¦Ü·|µo¥ÍÃö¸`¯}Ãa¡BÅܧΪº±¡§Î¡C
¤G¤Q¤C.¤°»ò¼Ëªº¤H®e©ö¿©±wÃþ­·Àã©ÊÃö¸`ª¢¡H
©Ê§O¤W¡A¥ÕºØ¤Hªº¿©±w¤ñ²v¸û¶ÀºØ¤H¨Ó±o°ª¡A¤k©Ê¸û¨k©Ê®e©ö¿©±w¦¹¯e¯f¡A¤k©Ê¥­§¡°ª¥X¤T­¿¥ª¥k¡A¯S§O¬O¥|¤Q·³¥H¤Wªº¤¤¦~°ü¤k¡A§ó¬OÃþ­·Àã©ÊÃö¸`ª¢ªº°ª¦MÀI¸s¡C¦AªÌ¦³®a±Ú¿ò¯f¥vªº¥Á²³¡A¤]¸û¥­±`¤H®e©ö¿©±wÃþ­·Àã©ÊÃö¸`ª¢¡C

¦^À³ªÌ¡G¸ô¤H¥Ò    ®É¶¡¡G2009/12/2 ¤U¤È 04:54:16
¤º  ®e¡G¤º®e¥R¹ê
  
¦^À³¦¹¤å³¹¡G ¦^À³ªÌ¡G

(¡° ¤£¦^À³¡A¥iªÅ¥Õ¡I¡I)

³Ì·s§ó·s¤é´Á¡G2009/12/2 ¤U¤È 04:53:36